WO2017183970A1 - Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis - Google Patents
Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis Download PDFInfo
- Publication number
- WO2017183970A1 WO2017183970A1 PCT/NL2017/050246 NL2017050246W WO2017183970A1 WO 2017183970 A1 WO2017183970 A1 WO 2017183970A1 NL 2017050246 W NL2017050246 W NL 2017050246W WO 2017183970 A1 WO2017183970 A1 WO 2017183970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ala
- early
- nutritional composition
- life stress
- neurogenesis
- Prior art date
Links
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 title claims abstract description 116
- 235000020778 linoleic acid Nutrition 0.000 title claims abstract description 116
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 116
- 230000004766 neurogenesis Effects 0.000 title claims abstract description 48
- 230000009467 reduction Effects 0.000 title claims description 24
- 208000010877 cognitive disease Diseases 0.000 title description 10
- 230000006999 cognitive decline Effects 0.000 title description 8
- 239000002253 acid Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 169
- 235000016709 nutrition Nutrition 0.000 claims abstract description 111
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 98
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 78
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 50
- 230000001149 cognitive effect Effects 0.000 claims abstract description 26
- 230000007423 decrease Effects 0.000 claims abstract description 26
- 230000035882 stress Effects 0.000 claims description 105
- 150000002632 lipids Chemical class 0.000 claims description 93
- 230000000971 hippocampal effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 230000004083 survival effect Effects 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- 241000024188 Andala Species 0.000 claims description 10
- 206010041092 Small for dates baby Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000015654 memory Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 6
- 235000004252 protein component Nutrition 0.000 claims description 6
- 230000003340 mental effect Effects 0.000 claims description 5
- 235000013350 formula milk Nutrition 0.000 claims description 4
- 235000021125 infant nutrition Nutrition 0.000 claims description 4
- 235000020218 follow-on milk formula Nutrition 0.000 claims description 3
- 230000006609 metabolic stress Effects 0.000 claims description 2
- 235000020209 toddler milk formula Nutrition 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 32
- 229930195729 fatty acid Natural products 0.000 description 32
- 239000000194 fatty acid Substances 0.000 description 32
- 150000004665 fatty acids Chemical class 0.000 description 32
- 150000003904 phospholipids Chemical group 0.000 description 30
- 235000005911 diet Nutrition 0.000 description 29
- 230000037213 diet Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 239000007788 liquid Substances 0.000 description 17
- 235000021243 milk fat Nutrition 0.000 description 17
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 13
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 150000003626 triacylglycerols Chemical class 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 10
- 108010046377 Whey Proteins Proteins 0.000 description 9
- 229920001542 oligosaccharide Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 8
- 235000014121 butter Nutrition 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000019771 cognition Effects 0.000 description 7
- 235000020247 cow milk Nutrition 0.000 description 7
- 235000021196 dietary intervention Nutrition 0.000 description 7
- 235000020256 human milk Nutrition 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 238000012347 Morris Water Maze Methods 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 150000002190 fatty acyls Chemical group 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000006886 spatial memory Effects 0.000 description 5
- 235000019871 vegetable fat Nutrition 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 4
- 241000282849 Ruminantia Species 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000003931 cognitive performance Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001310 location test Methods 0.000 description 4
- 238000000968 medical method and process Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 239000000944 linseed oil Substances 0.000 description 3
- 235000021388 linseed oil Nutrition 0.000 description 3
- 208000018773 low birth weight Diseases 0.000 description 3
- 231100000533 low birth weight Toxicity 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical group CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000030941 fetal growth restriction Diseases 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241001071905 Echium Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical group CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940049268 euthasol Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- -1 galacturonic acid oligosaccharides Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 230000009808 hippocampal neurogenesis Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 108010071421 milk fat globule Proteins 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940100557 purslane oil Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000020253 reindeer milk Nutrition 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000020255 yak milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention is in the field of nutritional compositions that have a beneficial effect on reducing early-life stress induced disorders, for example nutritional compositions that have a beneficial effect on reducing early-life stress induced cognitive decline, in particular early-life stress experienced by a human subject.
- the hippocampus is one of the very few brain regions that maintain the ability to generate new neurons throughout adult life. This process is named adult neurogenesis.
- the newly formed neurons are crucial to hippocampal functioning and are involved in specific aspects of hippocampus-dependent learning and memory.
- Naninck et al. in an article entitled "Chronic early life stress alters developmental and adult neurogenesis and impairs cognitive function in mice” in Hippocampus (2015) vol 25(3): 309-328, describe that early-life stress (ES) induces alterations in neurogenesis and also a reduction in survival of neurons formed in adulthood and that altered levels of neurogenesis are functionally relevant for cognitive impairments in adulthood.
- ES early-life stress
- early-life stress impairs cognitive functions and hippocampal neurogenesis in adulthood, also named 'adult neurogenesis.
- the authors express the hope that reaching understanding of the basis of this early-life stress induced alterations is profoundly important to mental health and disease and should provide the foundation of future therapeutic interventions.
- the present invention seeks to provide a way of influencing brain structure and functioning by means of nutritional intervention to relieve impairments due to early-life stress.
- the inventors surprisingly found that administration of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a low LA/ ALA weight ratio is effective in preventing early life stress induced decline in cognitive functioning.
- LA linoleic acid
- ALA alpha-linolenic acid
- mice that were subjected to early life stress and which were fed the nutritional composition according to the invention outperformed mice that were subjected to the same stress but which were fed the nutritional composition with a higher LA/ ALA ratio in object recognition test, object location tests and Morris Water Maze test executed in their adulthood, which indicated a significant preventive effect on the decline in cognitive functioning.
- object recognition test object recognition test
- object location tests object location tests
- Morris Water Maze test executed in their adulthood, which indicated a significant preventive effect on the decline in cognitive functioning.
- a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a low LA/ ALA weight ratio is effective in preventing early-life stress (ES) induced reduction in neurogenesis.
- LA linoleic acid
- ALA alpha-linolenic acid
- the dietary intervention with a nutritional composition comprising a low LA/ ALA weight ratio restored neurogenesis in adulthood after being exposed to early-life stress.
- Mice that were subjected to early-life stress and which were fed the nutritional composition according to the invention showed an unexpected hippocampal cell survival in their adulthood compared to mice that were subjected to the same stress but which were fed the nutritional composition with a higher LA/ ALA, which indicated a significant preventive effect on the reduction in neurogenesis.
- by dietary intervention negative consequences of stress early in life can be prevented. Applying a low dietary LA/ALA weight ratio early in life protects against early-life stress induced impairments, in particular protects against reduction in neurogenesis.
- the present invention thus concerns a method for preventing early life stress induced decline in cognitive functioning in a human subject, comprising administering to the subject a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12.
- the method for preventing early life stress induced decline in cognitive functioning is a non-medical method.
- the invention concerns a nutritional composition
- linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for use in preventing early life stress induced decline in cognitive functioning in a human subject.
- the invention can also be worded as the use of linoleic acid (LA) and alpha-linolenic acid (ALA) in the manufacture of a nutritional composition comprising LA and ALA in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early life stress induced decline in cognitive functioning in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early life stress induced decline in cognitive functioning in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the present invention also concerns a method for preventing early-life stress (ES) induced reduction in neurogenesis in a human subject, comprising administering to the human subject a nutritional composition comprising linoleic acid (LA) and alpha- linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12.
- the method for preventing early-life stress (ES) induced reduction in neurogenesis is a non-medical method.
- the present invention concerns a method for restoring neurogenesis in a human subject in adulthood after early-life stress, comprising administering to the human subject a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12.
- the method for restoring neurogenesis in adulthood is a non-medical method.
- the invention concerns a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for use in preventing early-life stress (ES) induced reduction in neurogenesis in a human subj ect.
- the invention concerns a nutritional composition
- linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for use in restoring neurogenesis in a human subject in adulthood after early-life stress.
- the invention can also be worded as the use of linoleic acid (LA) and alpha-linolenic acid (ALA) in the manufacture of a nutritional composition comprising LA and ALA in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early-life stress (ES) induced reduction in neurogenesis in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of linoleic acid (LA) and alpha-linolenic acid (ALA) in the manufacture of a nutritional composition comprising LA and ALA in a LA/ALA weight ratio in the range of 0.1 - 12 for restoring neurogenesis in a human subject in adulthood after early-life stress
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA ALA weight ratio in the range of 0.1 - 12 for preventing early-life stress (ES) induced reduction in neurogenesis in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for restoring neurogenesis in a human subject in adulthood after early-life stress.
- LA linoleic acid
- ALA alpha-linolenic acid
- the prevention of early-life stress (ES) induced reduction in neurogenesis occurs via preventing a decline in hippocampal cell survival in a human subject.
- the present invention concerns a method for preventing early-life stress (ES) induced decline in hippocampal cell survival in a human subject, comprising administering to the human subject a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ALA weight ratio in the range of 0.1 - 12.
- the method for preventing early-life stress (ES) induced decline in hippocampal cell survival is a non-medical method.
- the invention concerns a nutritional composition
- linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for use in preventing early-life stress (ES) induced decline in hippocampal cell survival in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of linoleic acid (LA) and alpha-linolenic acid (ALA) in the manufacture of a nutritional composition comprising LA and ALA in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early-life stress (ES) induced decline in hippocampal cell survival in a human subj ect.
- LA linoleic acid
- ALA alpha-linolenic acid
- the invention can also be worded as the use of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early-life stress (ES) induced decline in hippocampal cell survival in a human subject.
- LA linoleic acid
- ALA alpha-linolenic acid
- the nutritional composition that is to be administered according to the method of the invention comprises linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA ALA weight ratio in the range of 0.1 - 12.
- LA linoleic acid
- ALA alpha-linolenic acid
- the nutritional composition according to the invention may take any form of nutrition suitable to be administered to human subjects, preferably suitable to be administered to human subjects during early-life.
- the nutritional composition according to the invention may be a nutritional supplement, e.g. as an additive to a normal diet, a fortifier, to add to a normal diet, a complete nutrition or an infant nutrition suitable for feeding infants (e.g. infant formula or follow-on formula).
- the nutritional composition is suitable for feeding infants and/or toddlers.
- the nutritional composition is selected from an infant formula, a follow-on formula, a growing up milk and a nutritional supplement for pregnant women, most preferably the nutritional composition is an infant formula.
- it may constitute a complete nutrition or a supplement.
- the nutritional composition is a complete nutrition. It is preferred that the composition contains a lipid component, a digestible carbohydrate component and a protein component. It may further contain ingredients such as dietary fibres, minerals, vitamins, organic acids, nucleotides and flavouring agents.
- the lipid component preferably provides 2.9 to 6 g lipid per 100 kcal
- the protein component preferably provides 1.8 to 5.5 g per 100 kcal, suitably 1.8 to 2.5 g per 100 kcal
- the digestible carbohydrate component preferably provides 9 to 14 g per 100 kcal, of the composition.
- the amount of total calories is determined by the sum of calories derived from protein, lipids, digestible carbohydrates and non-digestible oligosaccharides
- the nutritional composition of the invention is typically an enteral composition, i.e. intended for oral administration. It is suitably administered in liquid form.
- the composition may comprise water in which the further components are dissolved or suspended.
- the composition is thus suitably a liquid, or a solid, typically a powder or tablet, which is reconstitutable with a liquid, suitably with water or other food grade aqueous liquids, to obtain a liquid composition, or in a liquid concentrate form that is to be diluted with water.
- the liquid composition has a viscosity below 100 mPa.s, more suitably below 60 mPa.s, more suitably below 35 mPa.s, even more suitably below 6 mPa.s as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s "1 .
- the composition preferably comprises 45 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid. This caloric density ensures an optimal ratio between water and calorie consumption.
- the osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 360 mOsmol/1.
- the nutritional composition comprises a lipid component, suitably a lipid component suitable for infant nutrition as known in the art.
- the lipid component of the present composition suitably provides 2.9 to 6.0 g, preferably 4 to 6 g per 100 kcal of the composition.
- the nutritional composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml.
- the lipid provides preferably 30 to 60 % of the total calories of the composition. More preferably the present composition comprises lipid providing 35 to 55 % of the total calories, even more preferably the present composition comprises lipid providing 40 to 50 % of the total calories.
- liquid form e.g.
- the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml .
- the nutritional composition comprises at least 15 wt.% lipid based on dry weight of the composition. Based on dry weight the nutritional composition preferably comprises 10 to 50 wt.%, more preferably 12.5 to 40 wt.% lipid, even more preferably 15 to 35 wt.% lipid, even more preferably 19 to 30 wt.% lipid.
- the lipid component comprised in the nutritional composition comprises linoleic acid (LA) and alpha-linolenic acid (ALA)
- LA linoleic acid
- LA alpha-linolenic acid
- ALA alpha-linolenic acid
- LA preferably is present in a sufficient amount in order to promote a healthy growth and development.
- the composition therefore preferably comprises less than 20 wt.% LA based on total fatty acids, preferably from 5 to 15 wt.%.
- the composition comprises over 5 wt.% LA based on fatty acids, preferably at least 10 wt.% based on total fatty acids.
- ALA is present in a sufficient amount to promote a healthy growth and development.
- the nutritional composition therefore preferably comprises at least 0.5 wt.% ALA based on total fatty acids preferably comprises at least 1.0 wt.% ALA based on total fatty acids.
- the composition comprises at least 1.4 wt.% ALA based on total fatty acids, more preferably at least 1.5 wt.%.
- the nutritional composition comprises less than 10 wt.% ALA, more preferably less than 5.0 wt.% based on total fatty acids.
- the nutritional composition comprises at least 10 wt.% LA and at least 1 wt.% ALA, preferably from 10 to 20 wt.% LA and from 1 to 5 wt.% ALA.
- a reduced LA/ ALA weight ratio when compared to conventional nutritional compositions, in particular conventional infant formulae, beneficially affects the cognition of the subject upon exposure to early life stress and prevents early life stress induced cognitive decline.
- the LA/ALA weight ratio of the nutritional composition according to the present invention is the range of 0.1 - 12, preferably in the range of 0.5 - 11, more preferably in the range of 0.8 - 10, more preferably in the range of 1 - 9, more preferbly in the range of 1 - 8.
- the lipid components such as LA and ALA, as well as the optionally present further components such as (LC-)PUFAs, may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
- the nutritional composition comprises triglycerides
- the composition comprises at least 70 wt.%, more preferably at least 80 wt.%, more preferably at least 85 wt.% triglycerides, even more preferably at least 90 wt.% triglycerides based on total lipids.
- the lipids may further comprise one or more of free fatty acids, monoglycerides and diglycerides.
- the LA/ ALA weight ratio of the nutritional composition according to the present invention is the range of 0.1 - 12, preferably in the range of 0.2 - 1 1, preferably in the range of 0.4 - 10, preferably in the range of 0.5 - 10, more preferably in the range of 0.6 - 10, more preferably in the range of 0.8 - 10, more preferably in the range of 1 - 8.
- the nutritional composition comprises triglycerides derived from vegetable fat.
- the nutritional composition preferably additionally, comprises phospholipids.
- the nutritional composition comprises phospholipids derived from non-human mammalian milk.
- the presence of vegetable lipids advantageously enables an optimal fatty acid profile, high in polyunsaturated fatty acids and more reminiscent to human milk fat.
- Using lipids from ruminant milk in particular cow's milk alone, or other domestic ruminant mammals, does not provide an optimal fatty acid profile. This less optimal fatty acid profile, such as a large amount of saturated fatty acids, is known to be not beneficial.
- the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, black currant seed oil, echium oil, coconut oil, palm oil and palm kernel oil.
- linseed oil flaxseed oil
- rape seed oil such as colza oil, low erucic acid rape seed oil and canola oil
- salvia oil such as colza oil, low erucic acid rape seed oil and canola oil
- perilla oil purslane oil
- lingonberry oil sea buckthorn oil
- hemp oil sunflower oil
- the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, canola oil, coconut oil, sunflower oil and high oleic sunflower oil.
- the composition comprises 30 to 99.5 wt.% vegetable lipids based on total lipids, more preferably 35 to 99 wt.%, even more preferably of 40 to 95 wt.%, based on total lipids.
- the nutritional composition comprises fat or lipids from mammalian milk, more preferably from ruminants milk, even more preferably cow's milk, goat milk, sheep milk, buffalo milk, yak milk, reindeer milk, and camel milk, most preferably cow's milk.
- the mammalian milk is not human milk.
- the nutritional composition comprises non-human mammalian milk fat.
- the mammalian milk fat component comprises at least 70 wt.% triglycerides, more preferably at least 90 wt.%, more preferably at least 97 wt.%.
- the mammalian milk fat is derived from the group consisting of butter, butter fat, butter oil, and anhydrous milk fat, more preferably anhydrous milk fat and butter oil.
- milk fat lipid sources are high in triglyceride levels.
- these lipid sources are in the form of a continuous fat phase or in a water-in-oil emulsion form. Using these sources of milk fat during the manufacture of the nutritional composition according to the invention enables the formation of lipid globules, wherein each globule comprises a mixture of vegetable fat and milk fat.
- the nutritional composition comprises 5 to 70 wt.% non-human mammalian milk lipids based on total lipids.
- the composition comprises 10 to 65 wt.%), even more preferably 15 to 60 wt.%, even more preferably 25 to 55 wt.% non- human mammalian milk lipids based on total lipids.
- these milk lipids are selected from the group consisting of butter, butter fat, butter oil, and anhydrous milk fat.
- the ratio of vegetable fat to milk fat ranges from 3/7 to 20/1.
- the composition also may comprise non-vegetable lipids and non-milk fat, such as animal fat other than milk fat, such as fish oil, and egg lipid, and microbial, algal, fungal or single cell oils.
- non-vegetable, non-milk fat is present in an amount of at most 10 wt.% based on total lipid, more preferably at most 5 wt.%.
- the lipid in the nutritional composition according to the invention comprises a fat source comprising long chain poly-unsaturated fatty acids (LC-PUFA), selected from the group consisting of fish oil, marine oil, algal oil, microbial oil, single cell oil and egg lipid in an amount of 0.25 to 10 wt.% based on total lipid, preferably in an amount of 0.5 to 10 wt.%.
- LC-PUFA long chain poly-unsaturated fatty acids
- the lipid is the form of lipid globules.
- the lipid globules When in liquid form, the lipid globules are emulsified in the aqueous phase.
- the lipid globules are present in a powder and the powder is suitable for reconstitution with water or another food grade aqueous phase.
- the lipid globules comprise a core and a surface.
- the core preferably comprises vegetable fat and milk fat and preferably comprises at least 80 wt.%, more preferably at least 90 wt.% triglycerides and more preferably essentially consists of triglycerides.
- triglyceride lipids that are present in the composition need necessarily be comprised in the core of lipid globules, but preferably a major part is, preferably more than 50% wt.%, more preferably more than 70 wt.%, even more preferably more than 85 wt.%, even more preferably more than 95 wt.%), most preferably more than 98 wt.% of the triglyceride lipids that are present in the composition are comprised in the core of lipid globules.
- the lipid globules have a mode diameter based on volume of above 1.0 ⁇ , preferably above 2.0 ⁇ , preferably above 2.5 ⁇ , more preferably above 3.0 ⁇ .
- the lipid globules preferably have a mode diameter based on volume of below 6.0 ⁇ , preferably below 5.5 ⁇ , more preferably of below 5.0 ⁇ .
- the lipid globules have a mode diameter based on volume from 2 to 6 ⁇ , preferably form 2.0 to 6.0 ⁇ , more preferably from 2.5 to 6.0 ⁇ , more preferably from 3.0 to 6.0 ⁇ , even more preferably from 3.0 to 5.5 ⁇ , even more preferably from 3.0 to 5.0 ⁇ .
- the mode diameter relates to the diameter which is the most present based on volume of total lipid, or the peak value in a graphic representation, having on the X-as the diameter and on the Y-as the volume (%).
- a suitable method to determine the volume of lipid globules and their size distribution is by using a Mastersizer particle size analyzer (Malvern Instruments, Malvern, UK), for example by the method described in Michalski et al, 2001, Lait 81 : 787-796.
- the specific surface area of lipid globules is the surface area per weight of lipid and decreases as the size of globules increases. The specific surface area of the lipid globules can thus be calculated from the particle size distribution of the lipid globules and the concentration and density of the lipid.
- the lipid globules comprised in the nutritional composition preferably have a specific surface area of 0.5 to 15 m 2 /g lipid, preferably from 1.0 to 10.0 m 2 /g, more preferably from 1.5 to 8.0 m 2 /g, even more preferably from 2.0 to 7.0 m 2 /g lipid.
- the nutritional composition preferably comprises phospholipids derived from (or "originating from”) non-human mammalian milk.
- Phospholipids derived from non- human mammalian milk include glycerophospholipids and sphingomyelin.
- the phospholipids are preferably comprised in a coating on the surface of the lipid globule.
- 'coating' is meant that the outer surface layer of the lipid globule comprises phospholipids, whereas these phospholipids are virtually absent in the core of the lipid globule. Not all phospholipids that are present in the nutritional composition need necessarily be comprised in the coating, but preferably a major part is.
- Preferably more than 30 wt.%, preferably more than 50 wt.%, more preferably more than 70 wt,%, even more preferably more than 85 wt.%, most preferably more than 95 wt.% of the phospholipids that are present in the composition are comprised in the coating of lipid globules.
- the nutritional composition comprises at least 0.5 wt.% phospholipids based on total lipid.
- phospholipids based on total lipid.
- at least 80 wt.% of the phospholipids is derived from non-human mammalian milk, more preferably at least 90 wt.%, even more preferably at least 95 wt.%) or 99% wt. or preferably all of the phospholipids is derived from non human mammalian milk.
- the phospholipids preferably comprise sphingomyelin.
- Sphingomyelins have a phosphorylcholine or phosphorylethanolamine molecule esterified to the 1 -hydroxy group of a ceramide.
- the nutritional composition comprises 0.05 to 10 wt.% sphingomyelin based on total lipid, more preferably 0.1 to 5 wt.%, even more preferably 0.2 to 2 wt.%.
- the nutritional composition comprises at least 15 wt.%, more preferably at least 20 wt.% sphingomyelin based on total phospholipids.
- the amount of sphingomyelin is below 50 wt.% based on total phospholipids.
- the phospholipids preferably comprise glycerophospholipids.
- Glycerophospholipids are a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine, PC), a serine group (in case of phosphatidyl serine, PS), an ethanolamine group (in case of phosphatidylethanolamine, PE), an inositol group (in case of phosphatidylinositol, PI) or a glycerol group (in case of phosphatidylglycerol, PG) attached to the phosphate group.
- a choline group in case of phosphatidylcholine, PC
- a serine group in case of phosphati
- the nutritional composition contains PC, PS, PI and/or PE, more preferably at least PS.
- the nutritional composition comprises at least 1 wt.%, preferably at least 2 wt.% phosphatidyl serine based on total phospholipids.
- the amount of phosphatidylserine is below 10 wt.% based on total phospholipids.
- Phospholipids derived from non-human mammalian milk include phospholipids isolated from milk lipid, cream lipid, cream serum lipid, butter serum lipid beta serum lipid, whey lipid, cheese lipid and/or buttermilk lipid.
- the phospholipids are obtained from milk cream.
- the phospholipids are preferably derived from milk of cows, mares, sheep, goats, buffalos, horses and camels, most preferably from cow's milk. It is most preferred to use a lipid extract isolated from cow's milk.
- a suitable source of phospholipids derived from non human mammalian milk is the fraction that can be isolated from milk called milk fat globule membrane (MFGM).
- MFGM milk fat globule membrane
- the phospholipids are conveniently located on the surface of lipid globules, i.e. comprised in a coating or outer layer.
- the lipid globules comprise a monolayer comprising phospholipids derived from milk fat.
- a suitable way to determine whether the polar lipids are located on the surface of the lipid globules is laser scanning microscopy or trans-electron microscopy.
- the concomitant use of polar lipids in particular phospholipids, derived from domestic animals milk and triglycerides derived from vegetable lipids therefore enables to manufacture coated lipid globules with a coating more similar to human milk, while at the same time providing an optimal fatty acid profile.
- Methods for obtaining lipid globules with such diameters and/or phospholipid-coatings are disclosed in WO 2010/ 0027258 and WO 2010/0027259.
- the nutritional composition comprises at least 0.3 wt.% butyric acid and/or acyl chain (BA), based on weight of total fatty acids.
- the nutritional composition comprises from 0.3 to 4.0 wt.%, preferably 0.3 to 3 wt.%, BA based on weight of total fatty acids.
- BA acyl chain
- the composition preferably comprises at least 0.3 wt.% BA, preferably at least 0.5 wt.%, more preferably at least 0.6 wt.%, more preferably at least 0.8 wt.%.
- the composition has a wt.% of BA below 4 wt.% based on weight of total fatty acids more preferable below 3 wt.%, more preferable below 2.5 wt.%.
- the nutritional composition comprises at least 5 wt.% medium chain fatty acids and/or acyl chains (MCFAs) based on total fatty acids, more preferably at least 7 wt.%).
- MCFA refer to fatty acids and/or acyl chains with a chain length of 8 to 12 carbon atoms.
- the composition advantageously comprises less than 15 wt.% MCFA based on total fatty acids, more preferably less than 10 wt.%.
- the nutritional composition comprises 10 to 25 wt.% polyunsaturated fatty acids and/or acyl chains (PUFAs) based on total fatty acids. Amounts above 25 wt.% are higher than present in human milk, and cause technological problems such as stability in the nutritional composition.
- the nutritional composition comprises long chain polyunsaturated fatty acids and/or acyl chains (LC-PUFAs), more preferably n-3 LC-PUFA.
- PUFAs comprise at least 20 carbon atoms in the fatty acyl chain and have 2 or more unsaturated bonds.
- the present composition comprises eicosapentaenoic acid and/or acyl chain (20:5 n3, EPA), docosapentaenoic acid and/or acyl chain (22:5 n3, DPA) and/or docosahexaenoic acid and/or acyl chain (22:6, n3, DHA), even more preferably DHA.
- eicosapentaenoic acid and/or acyl chain (20:5 n3, EPA)
- docosapentaenoic acid and/or acyl chain 22:5 n3, DPA
- docosahexaenoic acid and/or acyl chain 22:6, n3, DHA
- the content of n- 3 LC-PUFA in the nutritional composition more preferably DHA, preferably does not exceed 5 wt.% of the total fatty acid content.
- the nutritional composition comprises at least 0.15 wt.%, preferably at least 0.35 wt.%, more preferably at least 0.75 wt.%), n-3 LC-PUFA, more preferably DHA, of the total fatty acid content.
- the nutritional composition preferably comprises at least 0.25 wt% LC-PUFA based on total fatty acids.
- the lipid in the nutritional composition comprises a fat source comprising 0.25 wt.% to 5 wt.% LC-PUFA based on total fatty acids of which at least 0.15 wt% n-3 LC-PUFA based on total fatty acids selected from the group consisting of DHA, EPA, and DPA, more preferably DHA.
- the nutritional composition preferably comprises relatively low amounts of ARA.
- the n-6 LC-PUFA content more preferably ARA content, preferably does not exceed 5 wt.%, more preferably does not exceed 2.0 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.%), based on total fatty acids.
- the amount of n-6 LC-PUFA, preferably of ARA is preferably at least 0.02 wt.% more preferably at least 0.05 wt.%, more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.2 wt.%).
- the presence of preferably low amounts of ARA is especially beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
- the n-6 LC- PUFA/n-3 LC-PUFA weight ratio, more preferably ARA DHA weigh ratio is below 3, more preferably 2 or below, even more preferably 1 or below. Protein
- the nutritional composition preferably comprises a protein component.
- the protein component preferably provides 5 to 15% of the total calories.
- the composition comprises protein that provides 6 to 12% of the total calories. More preferably protein is present in the composition below 9% based on calories.
- Human milk comprises a lower amount of protein based on total calories than cow's milk.
- the protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids.
- the composition preferably comprises less than 12 wt.% protein, more preferably from 9.6 to 12 wt.%, even more preferably from 10 to 11 wt.%.
- the composition preferably comprises less than 1.5 g protein per 100 ml, more preferably from 1.2 to 1.5 g, even more preferably from 1.25 to 1.35 g.
- the source of the protein component should be selected in such a way that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
- protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred.
- the nutritional composition according to the invention comprises casein and whey protein.
- the protein source is preferably based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include a-lactalbumin and ⁇ - lactoglobulin. More preferably, the protein source is based on acid whey or sweet whey from which caseino-glyco-macropeptide (CGMP) has been removed.
- the composition comprises casein, preferably it comprises at least 3 wt.% casein based on dry weight.
- the casein is intact and/or non-hydrolyzed.
- protein includes peptides and free amino acids.
- the nutritional composition comprises a digestible carbohydrate component.
- the digestible carbohydrate component preferably provides 30 to 80% of the total calories of the composition.
- the digestible carbohydrate component provides 40 to 60% of the total calories.
- the composition preferably comprises 3.0 to 30 g digestible carbohydrate per 100 ml, more preferably 6.0 to 20, even more preferably 7.0 to 10.0 g per 100 ml. Based on dry weight the present composition preferably comprises 20 to 80 wt.%, more preferably 40 to 65 wt.% digestible carbohydrate.
- Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin.
- Lactose is the main digestible carbohydrate present in human milk. Lactose advantageously has a low glycemic index.
- the present composition preferably comprises lactose.
- the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% of the digestible carbohydrate is lactose. Based on dry weight the present composition preferably comprises at least 25 wt.% lactose, preferably at least 40 wt.%.
- the nutritional composition preferably comprises non-digestible oligosaccharides.
- the present composition comprises non-digestible oligosaccharides with a degree of polymerization (DP) from 2 to 250, more preferably from 3 to 60.
- Preferred non-digestible oligosaccharides are selected from fructo- oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto- oligosaccharides.
- the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
- Suitable non-digestible oligosaccharides are for example Vivinal GOS (FrieslandCampina DOMO), Raftilin HP or Raftilose (Orafti).
- the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 1 0 mg to 1.50 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the composition preferably comprises 0.25 wt.% to 20 wt.%, more preferably 0.5 wt.% to 10 wt.%, even more preferably 1.5 wt.% to 7.5 wt.%.
- composition preferably comprises other ingredients, such as vitamins, minerals according to international directives for infant nutrition, in particular infant formulae.
- the method according to the invention thus concerns administration of the nutritional composition according to the invention during the early life of the human subject.
- the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
- the inventors surprisingly found that the nutritional composition according to the invention is effective in preventing early-life stress induced reduction in neurogenesis in a human subject.
- the method according to the invention thus concerns administration of the nutritional composition according to the invention during the early-life of the human subject.
- the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
- preventing may also be referred to as “reducing”, “reducing the risk or occurrence of, “prophylaxis of or “(prophylactic) treatment of.
- the present use of "preventing early life stress induced decline in cognitive functioning” may also be worded as “stimulating cognitive functioning after exposure to early life stress” or “improving cognitive functioning after exposure to early life stress”.
- the present use of "preventing early-life stress induced reduction in neurogenesis” may also be worded as "protecting against early-life stress induced reduction in neurogenesis” or “restoring neurogenesis after exposure to early-life stress” or “stimulating neurogenesis after exposure to early-life stress” or “improving neurogenesis after exposure to early-life stress”.
- neurogenesis in a human subject in adulthood may also be worded as “adult neurogenesis”.
- “early life” typically lasts up to and including adolescence, e.g. up to the age of 18 years, preferably up to the age of 12 years, more preferably up to the age of 5 years, even more preferably up to the age of 36 months, most preferably up to the age of 12 months.
- Early life also includes the prenatal stage of the human subject, preferably the foetal stage, more preferably the foetal stage in the third trimester of pregnancy. In one embodiment, early life starts at birth.
- the human subject is preferably selected from the group of unborn foetuses, infants, toddlers, children, preadolescents and adolescents.
- the human subject is selected form unborn foetuses, infants and toddlers, more preferably from infants and toddlers, i.e. human subjects having an age of 0 - 36 months, most preferably the human subject is an infant, i.e. having an age of 0 - 12 months.
- the unborn foetus is preferably in the third trimester of pregnancy.
- Administration to the unborn foetus occurs via the pregnant mother, and the nutritional composition preferably takes the form of a nutritional supplement for pregnant women.
- the nutritional composition can also be in the form of a nutritional supplement for lactating women.
- the human subject is at risk or even at high risk of experiencing early life stress or is experiencing early life stress
- at (high) risk subjects are subjects, in particular children, from a lower socioeconomic status (e.g. children from families with an income level below average or a low level of education, e.g. not exceeding high school), children whose parents are separated or going through a separation, children separated from one of both parents, children whose parent are both working, neglected children, abused children, children whose parent(s) are suffering from stress, depression, depressed children, ill children, malnurtured children and children exposed to violence.
- children includes infants and toddlers, preferably the child is an infant.
- preterm infants and infants small for gestational age (SGA) infants Particular subjects that experience physical stress and/or mental stress are preterm infants and infants small for gestational age (SGA) infants.
- a preterm infant relates to an infant born before the standard period of pregnancy is completed, thus before 37 weeks pregnancy of the mother, i.e. before 37 weeks from the beginning of the last menstrual period of the mother.
- Preterm infants are also referred to as premature infants.
- SGA infants are those whose birth weight lies below the 10th percentile for that gestational age.
- Reasons for SGA can be several; for example, term or preterm infants can be born SGA because they have been the subject of intrauterine growth restriction (IUGR). Many preterm infants are also small for gestational age.
- IUGR intrauterine growth restriction
- Premature and/or SGA infants include low birth weight infants (LBW infants), very low birth weight infants (VLBW infants), and extremely low birth weight infants (ELBW infants).
- LBW infants are infants with a birth weight below 2500 g; this group includes term infants born SGA.
- VLBW and ELBW infants are almost always born preterm and are defined as infants with a birth weight below 1500 g or 1000 g, respectively.
- the human subject is a preterm infant, an infant born small for gestational age or both.
- the human subj ect is a male.
- administration of the nutritional composition according to the invention typically occurs when the human subject is 18 years old or younger, preferably the human subject has an age below 12 years, more preferably up to 5 years, even more preferably up to 36 months, most preferably up to 12 months.
- early life typically halts after adolescence, the beneficial effects on cognition and/or neurogenesis may last beyond early life, such as up to or even beyond adulthood. The effects may even last the entire lifespan of the subject.
- the prevention of early life stress induced cognitive decline and/or reduction in neurogenesis prolongs into adulthood.
- the prevention of declined cognitive functioning and/or reduced neurogenesis is manifest when the subject has reached adulthood or when the subject has reached an age of 18 years or higher, or even an age of 25 years or higher.
- the nutritional composition according to the invention exhibits a later-in- life effect on cognition and/or neurogenesis.
- the prevention of early life stress induced decline in cognitive functioning and/or reduction in neurogenesis is manifest later-in-life, preferably when the subject has reached an age of 5 years.
- the beneficial effect on cognition and/or neurogenesis prolongs at least 3 months, preferably at least 1 year, more preferably at least 5 years after administration of the nutritional composition according to the invention has halted.
- Exemplary of such a later-in-life effect is administration of the composition according to the invention to a foetus, infant or toddler, most preferably to an infant, while the preventive effect on early life stress induced declined cognition and/or reduction in neurogenesis is observed at an age of 5 years or older, more preferably at an age of 12 years or older, most preferably at an age of 18 years or older.
- Early life stress may take any known form. Typical stressors include psychological stressors, physiological stressors and physical stressors.
- the early life stress may the form of mental stress, physical stress, metabolic stress or any combination thereof.
- Exemplary stressors include disrupted families (e.g. divorce, separation, blending of families), separation from one or both parents (e.g. incarceration of a parent), maternal depression, both parents working, lack of attention by parent(s), exposure to violence, abuse (e.g. physical, mental, sexual), neglect (e.g. emotional, physical), death of a loved one (in particular death of a parent), illness (e.g. mental, physical), malnutrition.
- parent(s) may also refer to "care-taker(s)" or “guardian(s)".
- the early life stress is selected from malnutrition, maternal stress, depression and abuse.
- Early life stress induced cognitive decline is a specific type of cognitive decline, which is associated with many complex structures of the brain, such as the cerebral cortex, frontal cortex, hypothalamus, hippocampus and the perirhinal cortex. These structures in the brain play important roles in both cognition and regulating stress responses.
- the hippocampus for instance contains many stress hormone receptors and is highly plastic. Since these structures develop rapidly in the last trimester of pregnancy and postnatally until the age of about 16 years or beyond, they are particularly sensitive towards early life stress.
- the declined cognitive functioning preferably includes declined hippocampal-dependent cognitive functioning, or the declined cognitive functioning preferably is declined hippocampal-dependent cognitive functioning.
- Particularly preferred embodiments of cognitive functioning in the context of the present invention are (a) novel object recognition; (b) the preference for novelty; (c) attention for (change in) surroundings; (d) non-spatial (object) memory; (e) spatial memory and (f) spatial reference memory, but also include novel object recognition and/or novel object location, or hippocampal-dependent memory (especially long term spatial memory).
- the prevention of the reduction in neurogenesis is via preventing a decline in hippocampal cell survival.
- the invention also concerns as such preventing early-life stress induced decline in hippocampal cell survival by administration of the nutritional composition according to the invention during the early-life of the human subject.
- the present use of "preventing early-life stress induced decline in hippocampal cell survival" may also be worded as "stimulating hippocampal cell survival after exposure to early-life stress” or "improving hippocampal cell survival after exposure to early-life stress”.
- mice with litters were exposed to early life stress paradigm consisting of limited nest/ bedding material as described by Naninck et al., Hippocampus 2015, 25:309-328.
- the stress paradigm was initiated at 2 days after birth of litter (PN2), and lasted until PN9. Litters were weaned at PN21
- the experimental diets were semisynthetic diets with a macronutrient and micronutrient composition according to American Institute of Nutrition formulation of ATN93-G purified diets for laboratory rodent (Reeves 1993), and differed only in fatty acid composition with respect to linoleic (LA) and alpha linolenic (ALA) content, see table 1.
- LA linoleic
- ALA alpha linolenic
- Table 1 Fatty acid composition of the experimental diets.
- mice were subjected to a novel object recognition test (ORT) at day 120.
- ORT object recognition test
- This test is a behavioural procedure to study preference for non-spatial object memory based on the innate preference of mice for novelty.
- mice had to discriminate between a novel object and an object that they had explored previously (familiar).
- mice were habituated for five minutes/day to the testing arena that consisted of a rectangular plastic box.
- mice had five minutes to explore two identical objects (9,5 cm high glass bottles) that were placed in the box 12 cm from each other and 11 cm from the wall.
- OLT Object location tests
- mice had five minutes to explore the objects and their location.
- 24h post-training one object was moved to a novel position in the arena and mice were reintroduced into the arena for five min to explore.
- Time spent exploring was recorded as before and the ratio of novel/familiar object exploration time was calculated. The results are shown in table 2.
- the ratio novel/old exploration time during ORT is reduced by previous exposure to early life stress in the animals that were fed Diet A indicating that the animals were not able to distinguish between the object they have already seen and the new one that they are seeing for the first time.
- This index is not reduced by the stress paradigm in animals that were fed Diet B.
- the difference between the two stressed diet group is statistically significant and indicate that Diet B can prevent stress induced impairments in cognitive performance, in particular novelty preference and non spatial memory performance.
- mice were also subjected to a Morris Water Maze test at PN 140 also known as Morris Water Maze navigation task, is a behavioral procedure to study cognitive function, in particular spatial learning and memory.
- animals were trained to locate a hidden platform based on environmental cues.
- a platform was submerged just below water surface at a fixed position in a round water tank. The tank was in a room with fixed cues on the walls that were visible from the water surface in the tank.
- mice were trained twice daily (inter trial interval 10 minutes) to locate the hidden platform.
- animals were placed in the water of the tank and had to locate the platform within 60 seconds. Between trials the starting position of the animal was varied between one of the three quadrants without the platform.
- the platform was removed from the pool for a single probe trial, in which the time spent in the target quadrant was recorded. This trial is referred to as probe trial.
- the results are shown in table 3.
- Table 3 time (%) spent in the target quadrant in the probe trial of the Morris Water Maze.
- the percentage of time spent in the target quadrant is reduced by previous exposure to early life stress in the animals that were fed Diet A indicating that the animals did not remember as well where the platform was located. Exposure to Diet B, however, prevented the stress- induced impairment in time spent in the target quadrant. This is indicative for an improved cognitive performance, in particular long term (spatial) memory performance.
- mice were injected intraperitoneally with 100 mg/kg BrdU (10 mg/mL dissolved in sterile saline + 0.007M NaOH) for 2 times a day on 4 consecutive days. Four weeks after the last injections, mice were transcardially perfused at P230.
- mice were anesthetized by intraperitoneal inj ection of pentobarbital (Euthasol®, 120 mg/kg) and transcardial perfused with initially 0.9% saline, which was followed by 4% paraformaldehyde (PFA) in phosphate buffer (PB 0.1M, pH 7.4).
- PFA paraformaldehyde
- PB 0.1M phosphate buffer
- Whole perfused brains were carefully removed, post-fixated with 4% PFA in O. l .M PB at 4°C for 24 h and stored in PB with 0.01% sodium azide at 4°C. Prior to brain slicing, perfused brains were cryoprotected in 30% sucrose in 0.1M PB.
- frozen brains were sliced in 40 ⁇ thick coronal sections and divided over 6 parallel series by a microtome and stored in antifreeze (30% Ethylene glycol, 20% Glycerol, 50% 0.05M PBS; company) at -20°C.
- BrdU-labeled cells were detected using fluorescent immunohistochemistry. Brain slices (from one of the 6 parallel series) were mounted on glass (Superfrost Plus slides, Menzel, Braunschweig, Germany), followed by heat-induced antigen retrieval in 0.1M citrate buffer (pH 6.0) using a microwave (Samsung M6235) at ⁇ 95°C for 15 min (5 min at 800 Watt, 5 min at 400 Watt, 5 min at 200 Watt).
- the figure represents the hippocampal cell survival measured as labeled BrdU cells in the denate gyrus (DG) for diet A and diet B of the control group not having been subjected to early-life stress (open bars on the left side) and the group that has been subjected to early-life stress (black filled bars on the right).
- the hippocampal cell survival after having been subjected to early-life stress is significantly lower for diet A compared to diet B.
- the hippocampal cell survival for diet B after having been subjected to early-life stress is the same as that for both diets after not after having been subjected to early-life stress.
- nutritional intervention with a diet having a low LA/ ALA ratio has a preventive effect on reducing neurogenesis after early-life stress or in other words protects against early-life stress induced reduction in neurogenesis.
- nutritional intervention with a diet having a low LA/ALA ratio restores neurogenesis in adulthood after early-life stress.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Pediatric Medicine (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17719941.1A EP3445353A1 (en) | 2016-04-18 | 2017-04-18 | Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis |
CN201780037737.2A CN109310662A (en) | 2016-04-18 | 2017-04-18 | For reducing cognition decline/nerve to occur reduction linoleic acid and alpha-linolenic acid of the induction of life early-life stress |
BR112018071493-3A BR112018071493A2 (en) | 2016-04-18 | 2017-04-18 | uses of linoleic acid (la) and alpha linolenic acid (ala) in the manufacture of nutritional composition, nutritional composition, method for preventing decline in induced cognitive functioning, and method for preventing reduction in early stress induced neurogenesis |
RU2018140486A RU2741495C2 (en) | 2016-04-18 | 2017-04-18 | Linoleic acid or alpha-linolenic acid for use in reducing cognitive disorders/early neurogenesis induced by early life stress |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2016/050271 WO2017183956A1 (en) | 2016-04-18 | 2016-04-18 | Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline |
NLPCT/NL2016/050271 | 2016-04-18 | ||
EP16188154.5 | 2016-09-09 | ||
EP16188154 | 2016-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017183970A1 true WO2017183970A1 (en) | 2017-10-26 |
Family
ID=58639027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2017/050246 WO2017183970A1 (en) | 2016-04-18 | 2017-04-18 | Linoleic acid and alpha-li nolenic acid for use for reducing early-life stress induced cognitive decline/reduction in neurogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3445353A1 (en) |
CN (1) | CN109310662A (en) |
BR (1) | BR112018071493A2 (en) |
RU (1) | RU2741495C2 (en) |
WO (1) | WO2017183970A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024121222A1 (en) * | 2022-12-06 | 2024-06-13 | N.V. Nutricia | Infant formula for improving cognitive development |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078530A2 (en) * | 2000-04-13 | 2001-10-25 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
WO2007073192A2 (en) * | 2005-12-23 | 2007-06-28 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
WO2009002145A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2010027259A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with coated lipid globules |
WO2011115476A1 (en) * | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
US20140121276A1 (en) * | 2011-06-29 | 2014-05-01 | National Center Of Neurology And Psychiatry | Method for alleviating fear memory |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000040A1 (en) * | 2003-06-24 | 2005-01-06 | University Of Kansas Medical Center | Infant formula |
ATE509624T1 (en) * | 2005-12-23 | 2011-06-15 | Nutricia Nv | COMPOSITION CONTAINING POLYUNSATURATED FATTY ACIDS, PROTEINS, MANGANEOUS AND/OR MOLYBDENES AND NUCLEOTIDES/NUCLEOSIDES, FOR THE TREATMENT OF DEMENTIA |
AU2008269728B2 (en) * | 2007-06-26 | 2013-10-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
CN101773223B (en) * | 2010-02-11 | 2013-01-02 | 圣元营养食品有限公司 | Infant food composite |
ES2725610T3 (en) * | 2013-12-12 | 2019-09-25 | Nestle Sa | Synthetic milk compositions comprising polyunsaturated fatty acids (PUFAS) to promote the healthy establishment of cognitive function in infants and male and female children |
-
2017
- 2017-04-18 BR BR112018071493-3A patent/BR112018071493A2/en not_active Application Discontinuation
- 2017-04-18 CN CN201780037737.2A patent/CN109310662A/en active Pending
- 2017-04-18 WO PCT/NL2017/050246 patent/WO2017183970A1/en active Application Filing
- 2017-04-18 RU RU2018140486A patent/RU2741495C2/en active
- 2017-04-18 EP EP17719941.1A patent/EP3445353A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001078530A2 (en) * | 2000-04-13 | 2001-10-25 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof |
WO2007073192A2 (en) * | 2005-12-23 | 2007-06-28 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
WO2009002145A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2010027259A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with coated lipid globules |
WO2010027258A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2011115476A1 (en) * | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
US20140121276A1 (en) * | 2011-06-29 | 2014-05-01 | National Center Of Neurology And Psychiatry | Method for alleviating fear memory |
Non-Patent Citations (9)
Title |
---|
A. KOROSI ET AL: "Early-life stress mediated modulation of adult neurogenesis and behavior", BEHAVIOURAL BRAIN RESEARCH., vol. 227, no. 2, 1 February 2012 (2012-02-01), NL, pages 400 - 409, XP055355375, ISSN: 0166-4328, DOI: 10.1016/j.bbr.2011.07.037 * |
ARTEMIS P SIMOPOULOS: "Evolutionary Aspects of Diet: The Omega-6/Omega-3 Ratio and the Brain", MOLECULAR NEUROBIOLOGY, HUMANA PRESS INC, NEW YORK, vol. 44, no. 2, 29 January 2011 (2011-01-29), pages 203 - 215, XP019956969, ISSN: 1559-1182, DOI: 10.1007/S12035-010-8162-0 * |
BERNARD JONATHAN Y ET AL: "The association between linoleic acid levels in colostrum and child cognition at 2 and 3 y in the EDEN cohort (vol 77, pg 829, 2015)", PEDIATRIC RESEARCH, vol. 78, no. 3, September 2015 (2015-09-01), pages 356, XP055326920 * |
FENOGLIO K A ET AL: "Hippocampal neuroplasticity induced by early-life stress: Functional and molecular aspects", FRONTIERS IN NEUROENDOCRINOLOGY, ACADEMIC PRESS, SAN DIEGO, US, vol. 27, no. 2, 1 July 2006 (2006-07-01), pages 180 - 192, XP024922395, ISSN: 0091-3022, [retrieved on 20060701], DOI: 10.1016/J.YFRNE.2006.02.001 * |
GAO HUI ET AL: "Long-Term Dietary Alpha-Linolenic Acid Supplement Alleviates Cognitive Impairment Correlate with Activating Hippocampal CREB Signaling in Natural Aging Rats", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 53, no. 7, 2 September 2015 (2015-09-02), pages 4772 - 4786, XP036017888, ISSN: 0893-7648, [retrieved on 20150902], DOI: 10.1007/S12035-015-9393-X * |
LUCASSEN ET AL., TRENDS IN NEUROSCIENCES, vol. 36, 2013, pages 621 - 631 |
MICHALSKI ET AL., LAIT, vol. 81, 2001, pages 787 - 796 |
NANINCK ET AL., HIPPOCAMPUS, vol. 25, 2015, pages 309 - 328 |
NANINCK ET AL.: "Chronic early life stress alters developmental and adult neurogenesis and impairs cognitive function in mice", HIPPOCAMPUS, vol. 25, no. 3, 2015, pages 309 - 328, XP055355767, DOI: doi:10.1002/hipo.22374 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024121222A1 (en) * | 2022-12-06 | 2024-06-13 | N.V. Nutricia | Infant formula for improving cognitive development |
Also Published As
Publication number | Publication date |
---|---|
CN109310662A (en) | 2019-02-05 |
RU2018140486A (en) | 2020-05-19 |
BR112018071493A2 (en) | 2019-02-19 |
EP3445353A1 (en) | 2019-02-27 |
RU2018140486A3 (en) | 2020-07-14 |
RU2741495C2 (en) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013277900B2 (en) | Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat | |
EP2753190B1 (en) | Use of infant formula with cholesterol | |
US20180310605A1 (en) | Infant formula with milk fat for promoting healthy growth | |
EP2753191B1 (en) | Use of infant formula with large lipid globules | |
WO2018178310A1 (en) | Infant formula for improved eating behaviour | |
AU2022204529B2 (en) | Nutritional composition for improving cell membranes | |
AU2020396275B2 (en) | Infant formula with special lipid architecture for improving postnatal growth of infants born to overweight and obese mothers | |
RU2741495C2 (en) | Linoleic acid or alpha-linolenic acid for use in reducing cognitive disorders/early neurogenesis induced by early life stress | |
EP3599895B1 (en) | Infant formula for improved eating behaviour | |
WO2017183956A1 (en) | Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline | |
WO2024121222A1 (en) | Infant formula for improving cognitive development | |
NZ795279A (en) | Nutritional composition for improving cell membranes | |
NZ621230B2 (en) | Use of infant formula with large lipid globules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018071493 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017719941 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017719941 Country of ref document: EP Effective date: 20181119 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17719941 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112018071493 Country of ref document: BR Kind code of ref document: A2 Effective date: 20181018 |